Efficacy of a novel antigen-decorated adenoviral vaccine platform against porcine respiratory coronavirus infection in a large natural host

Read full text
Authors: Sanis Wongborphid, Emily J. Briggs, Rebecca A Russell, Shafiyeel Chowdhury, Ashutosh Vats, Bethany G. Charlton, Louisa M. Rose, Rosa María Chávez Dagóstino, Lesley A. H. Bowman, Christine S. Rollier, Catherine F. Hatton, Jean-Rémy Sadeyen
+11 more Munir Iqbal, Ellen C. Moorhouse, Tiphaine Cayol, Erica Bickerton, Danish Munir, Francisco Javier Salguero, Basudev Paudyal, Sarah Keep, Sumi Biswas, Matthew D. J. Dicks, Elma Z. Tchilian
Cited by: 0
References: 38

Abstract

Porcine respiratory coronavirus (PRCV) infection in pigs provides a physiologically and immunologically relevant large-animal model for acute respiratory coronavirus disease and vaccine evaluation. We investigated a replication-defective adenovirus (Ad) vaccine platform that enables display of antigens on the Ad capsid surface using the DogTag/DogCatcher protein superglue system. Ad vectors encoding the PRCV135 Spike (S) and Nucleocapsid (N) proteins were evaluated with or without surface decoration with the PRCV135 Spike receptor-binding domain (RBD). Both Ad(SN) and RBD-decorated Ad(SN)-RBD135 vaccines were protective against PRCV135 challenge. RBD135 decoration significantly enhanced neutralizing antibody titers in serum and bronchoalveolar lavage. In contrast, aerosol immunization with Ad(N) induced robust T cell responses but no protection. A multivalent cocktail of RBD-decorated Ad vectors targeting PRCV, porcine hemagglutinating encephalomyelitis virus (PHEV), and porcine deltacoronavirus (PDCoV) elicited antibodies against all three pathogens. This study demonstrates the versatility and potency of antigen-decorated Ad vectors as a platform for next-generation coronavirus vaccines in a relevant large natural host model.

Fields of Study & Subjects

Animal Virus Infections Studies SARS-CoV-2 and COVID-19 Research Virus-based gene therapy research

Publication details

Journal / source
Vaccine
Publisher
Elsevier BV
Volume
80
Pages
128556–128556
Publication date
1 April 2026
Language
EN